PureTech to present at Jefferies Conference

RNS Number : 7437Z
PureTech Health PLC
31 May 2016
 

PureTech to present at the Jefferies 2016 Healthcare Conference in New York

 

Boston, Massachusetts, May 31, 2016 - PureTech Health plc ("PureTech" or the "Company", LSE: PRTC), a cross-disciplinary healthcare company developing novel medicines focused on the brain, gut and immune system, today announces that Daphne Zohar, PureTech's Chief Executive Officer, will be presenting at the Jefferies 2016 Healthcare Conference in New York, NY being held on June 7-10, 2016.

 

PureTech's presentation is scheduled for Thursday 9 June 2016 at 9:30 am EDT and will be followed by a breakout session.

 

About PureTech Health

PureTech Health (PureTech Health plc, PRTC.L) is a cross-disciplinary healthcare company focused on areas of growing scientific and technical insights that it believes are at an important inflection point, including the central nervous, gastro-intestinal and immune systems, and the interactions and signalling between them. PureTech has a pipeline of more than 30 programmes and has approximately 20 clinical studies across its pipeline, targeting multi-billion dollar market opportunities. PureTech's advanced programs include five with human proof-of-concept and multiple with pivotal or registration study readouts in the next two years. PureTech has over 220 patents and patent applications. PureTech's leading team and board, along with an advisory network of more than 60 expert founder-scientists and advisors across multiple disciplines, gives PureTech access to potentially ground-breaking science and technological innovation. With healthcare undergoing major transformation, PureTech believes it is well positioned to develop and launch medicines for the 21st century. For more information, visit www.puretechhealth.com and connect with us on Twitter.

 

#  #  #

 

Enquiries:

 

PureTech

Julie DiCarlo, Senior Vice President, Communications & Investor Relations

 

+1 617 226 4819

FTI Consulting (Communications adviser to PureTech)

Ben Atwell

Matthew Cole

+44 (0) 20 3727 1000

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAAKDDKDBKDPPN
UK 100

Latest directors dealings